摘要
D-二聚体是纤维蛋白特异性降解产物,是反映血液高凝和继发性纤溶亢进的一项常用实验室指标。慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)常伴有血液高凝,可能与炎症、缺氧、酸中毒等众多因素有关,使其发生静脉血栓栓塞症(venous thrombosis,VTE)的风险增加,是慢阻肺急性发作(acute exacebation of COPD,AECOPD)及死亡的重要危险因素。血液高凝继发性激活纤溶反应,产生D-二聚体,其浓度与病情有关,可用于评估COPD的严重程度,同时在COPD合并疾病及COPD的治疗、预后方面有一定指导作用。本文主要对D-二聚体在COPD中的临床研究进展作简要综述。
D-dimer is a specific degradation product of fibrin and a common laboratory index reflecting blood hypercoagulability and secondary hyperfibrinolysis. Chronic obstructive pulmonary disease(COPD) is often accompanied by hypercoagulability, which may be related to many factors such as inflammation, hypoxia,acidosis and so on,which increases the risk of venous thrombosis(VTE) and is an important risk factor for acute exacebation of COPD(AECOPD) and death of patients with COPD.The blood hypercoagulability secondarily activates fibrinolytic system to produce D-dimer whose concentration is related to the condition of the disease,and it can be used to evaluate the severity of COPO and also plays a guiding role in the COPD with related diseaseas and treatment and prognosis of the COPD. This article reviews the clinical research progress of plasma D-dimer in COPD.
作者
尚春芳
吴世满
SHANG Chunfang;WU Shiman(Shanxi Medical University, Shanxi ,Taiyuan 030000 ,China)
出处
《河北医药》
CAS
2019年第12期1882-1887,共6页
Hebei Medical Journal
